Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations By Ogkologos - October 22, 2025 130 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma Mortality Trends for Most Cancers Remain Favourable In the EU, Although the Absolute Number of Cancer Deaths Is Not Declining Due To Population Ageing Abemaciclib Improves PFS at Six Months Among Patients with High-Grade Meningiomas Harbouring NF2 or CDK Pathway Alterations MOST POPULAR Pregnancy is Safe After Early Breast Cancer in Young Women with... July 17, 2020 A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with... January 16, 2026 Rationale Explained for Granting EMA Authorisation for Extended Use of Nivolumab... November 18, 2020 Gentle regular exercise could reduce the risk of liver cancer in... February 15, 2021 Load more HOT NEWS For Women Returning from Breast Cancer Treatment, Work Often Changes Involuntarily First Mature Estimation of Median OS for Selpercatinib in Patients with... TAT 2021 Honorary Award: A Recognition in Cancer Drug Development to... What to Know About Navigating Your Cancer Care During An Extreme...
